Market research
ONTX Onconova Therapeutics Inc
US USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 8.33
- Dividend yield
- Not available
- Beta
- 0.0
Profile
Instrument facts
- Exchange
- US
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68232V8019
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 8.33
- Dividend yield
- Not available
- Beta
- 0.0
About
About Onconova Therapeutics Inc
Under normal circumstances, the fund will invest at least 80% of the value of its net assets, plus any borrowings for investment purposes, in financial instruments (for example, swaps and futures) that, in the aggregate, provide leveraged exposure to the Underlying Security equal to approximately two times its daily performance. It is non-diversified.
Research context
Onconova Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ONTX discussion.
5 years, 6 months ago
Onconova Therapeutics, Inc is currently in a long term downtrend where the price is trading 35.8% below its 200 day moving average.
From a valuation standpoint, the stock is 46.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 714.9.
Onconova Therapeutics, Inc's total revenue rose by 90.0% to $57K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-6K since the same quarter in the previous year.
Finally, its free cash flow fell by 2.3% to $-5M since the same quarter in the previous year.
Based on the above factors, Onconova Therapeutics, Inc gets an overall score of 3/5.